Keeping Track: Personalized Medicine For Lung Cancer Evolves; Idelvion Is CBER's First Novel Approval In 2016
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Bromday Larger Bottle Gets Wink From Advisory Cmte. Still Torn On Safety
FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee said there are good reasons for FDA to approve larger fill sizes for Ista’s ocular anti-inflammatory drops, although there isn’t enough evidence to say using them in both eyes would be safe.
US FDA’s New Drug Median Review Time Held Steady At Eight Months In 2021
The median review time for novel agents at CDER hasn’t changed in five years. Our infographic offers a look at the tortoises and hares (all of them winners because they got approved).
Keeping Track: Breakthrough Designations Fuel Expansion Of Genomically-Defined NSCLC Therapy
News and highlights from the Pink Sheet’s US FDA Performance Tracker